Cargando…
Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines
New influenza strains are constantly emerging, causing seasonal epidemics and raising concerns to the risk of a new global pandemic. Since vaccination is an effective method to prevent the spread of the disease and reduce its severity, the development of robust bioprocesses for producing pandemic in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414887/ https://www.ncbi.nlm.nih.gov/pubmed/36016198 http://dx.doi.org/10.3390/vaccines10081310 |
_version_ | 1784776097335869440 |
---|---|
author | Yang, Zeyu Xu, Xingge Silva, Cristina A. T. Farnos, Omar Venereo-Sanchez, Alina Toussaint, Cécile Dash, Shantoshini González-Domínguez, Irene Bernier, Alice Henry, Olivier Kamen, Amine |
author_facet | Yang, Zeyu Xu, Xingge Silva, Cristina A. T. Farnos, Omar Venereo-Sanchez, Alina Toussaint, Cécile Dash, Shantoshini González-Domínguez, Irene Bernier, Alice Henry, Olivier Kamen, Amine |
author_sort | Yang, Zeyu |
collection | PubMed |
description | New influenza strains are constantly emerging, causing seasonal epidemics and raising concerns to the risk of a new global pandemic. Since vaccination is an effective method to prevent the spread of the disease and reduce its severity, the development of robust bioprocesses for producing pandemic influenza vaccines is exceptionally important. Herein, a membrane chromatography-based downstream processing platform with a demonstrated industrial application potential was established. Cell culture-derived influenza virus H1N1/A/PR/8/34 was harvested from benchtop bioreactor cultures. For the clarification of the cell culture broth, a depth filtration was selected as an alternative to centrifugation. After inactivation, an anion exchange chromatography membrane was used for viral capture and further processing. Additionally, two pandemic influenza virus strains, the H7N9 subtype of the A/Anhui/1/2013 and H3N2/A/Hong Kong/8/64, were successfully processed through similar downstream process steps establishing optimized process parameters. Overall, 41.3–62.5% viral recovery was achieved, with the removal of 86.3–96.5% host cell DNA and 95.5–99.7% of proteins. The proposed membrane chromatography purification is a scalable and generic method for the processing of different influenza strains and is a promising alternative to the current industrial purification of influenza vaccines based on ultracentrifugation methodologies. |
format | Online Article Text |
id | pubmed-9414887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94148872022-08-27 Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines Yang, Zeyu Xu, Xingge Silva, Cristina A. T. Farnos, Omar Venereo-Sanchez, Alina Toussaint, Cécile Dash, Shantoshini González-Domínguez, Irene Bernier, Alice Henry, Olivier Kamen, Amine Vaccines (Basel) Article New influenza strains are constantly emerging, causing seasonal epidemics and raising concerns to the risk of a new global pandemic. Since vaccination is an effective method to prevent the spread of the disease and reduce its severity, the development of robust bioprocesses for producing pandemic influenza vaccines is exceptionally important. Herein, a membrane chromatography-based downstream processing platform with a demonstrated industrial application potential was established. Cell culture-derived influenza virus H1N1/A/PR/8/34 was harvested from benchtop bioreactor cultures. For the clarification of the cell culture broth, a depth filtration was selected as an alternative to centrifugation. After inactivation, an anion exchange chromatography membrane was used for viral capture and further processing. Additionally, two pandemic influenza virus strains, the H7N9 subtype of the A/Anhui/1/2013 and H3N2/A/Hong Kong/8/64, were successfully processed through similar downstream process steps establishing optimized process parameters. Overall, 41.3–62.5% viral recovery was achieved, with the removal of 86.3–96.5% host cell DNA and 95.5–99.7% of proteins. The proposed membrane chromatography purification is a scalable and generic method for the processing of different influenza strains and is a promising alternative to the current industrial purification of influenza vaccines based on ultracentrifugation methodologies. MDPI 2022-08-13 /pmc/articles/PMC9414887/ /pubmed/36016198 http://dx.doi.org/10.3390/vaccines10081310 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yang, Zeyu Xu, Xingge Silva, Cristina A. T. Farnos, Omar Venereo-Sanchez, Alina Toussaint, Cécile Dash, Shantoshini González-Domínguez, Irene Bernier, Alice Henry, Olivier Kamen, Amine Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines |
title | Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines |
title_full | Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines |
title_fullStr | Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines |
title_full_unstemmed | Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines |
title_short | Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines |
title_sort | membrane chromatography-based downstream processing for cell-culture produced influenza vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414887/ https://www.ncbi.nlm.nih.gov/pubmed/36016198 http://dx.doi.org/10.3390/vaccines10081310 |
work_keys_str_mv | AT yangzeyu membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT xuxingge membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT silvacristinaat membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT farnosomar membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT venereosanchezalina membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT toussaintcecile membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT dashshantoshini membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT gonzalezdominguezirene membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT bernieralice membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT henryolivier membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines AT kamenamine membranechromatographybaseddownstreamprocessingforcellcultureproducedinfluenzavaccines |